Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Celgene Corporation    CELG

CELGENE CORPORATION

(CELG)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Celgene : Says EC Approves two Triplet Regimens for Multiple Myeloma

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/16/2019 | 09:31am EDT

By Michael Dabaie

Celgene Corp. (CELG) said the European Commission has approved two new triplet regimens based on Celgene's Revlimid and Imnovid.

Revlimid in combination with bortezomib and dexamethasone is now indicated for the treatment of adult patients with previously untreated multiple myeloma who aren't eligible for transplant.

Imnovid, in combination with bortezomib and dexamethasone, is now indicated for the treatment of adult patients with multiple myeloma who have received at least one prior treatment regimen including lenalidomide, the company said.

The triplet regimens aren't approved for use in the U.S., Celgene said.

Write to Michael Dabaie at michael.dabaie@wsj.com

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on CELGENE CORPORATION
05/21CELGENE : and the Multiple Sclerosis Association of America Team Up to Launch MS..
BU
05/17CELGENE : Receives European Commission Approvals for REVLIMID and IMNOVID based ..
AQ
05/16CELGENE : Says EC Approves two Triplet Regimens for Multiple Myeloma
DJ
05/16CELGENE : Receives European Commission Approvals for REVLIMID® (lenalidomide) an..
BU
05/15CELGENE : to Highlight New and Updated Hematology and Oncology Clinical Data at ..
BU
05/13CELGENE : Says FDA Grants Breakthrough Designation to Pomalyst
DJ
05/13CELGENE CORPORATION : Announces POMALYST® Granted Breakthrough Therapy Designati..
BU
05/13ENZO BIOCHEM INC. : Announces Issuance of United States Patent for Treatment of ..
AQ
05/10LYFEBULB AND CELGENE ANNOUNCE FINALI : An Innovation Challenge"
PR
05/10PATRICK THOMAS : Biotech Industry Woos Talent With Top Pay -- WSJ
DJ
More news
Financials ($)
Sales 2019 17 137 M
EBIT 2019 9 896 M
Net income 2019 6 372 M
Debt 2019 8 583 M
Yield 2019 -
P/E ratio 2019 11,34
P/E ratio 2020 9,64
EV / Sales 2019 4,47x
EV / Sales 2020 3,71x
Capitalization 67 959 M
Chart CELGENE CORPORATION
Duration : Period :
Celgene Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CELGENE CORPORATION
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 21
Average target price 97,0 $
Spread / Average Target 0,66%
EPS Revisions
Managers
NameTitle
Mark J. Alles Chairman, President, CEO & COO
David V. Elkins Chief Financial Officer & Executive Vice President
Joseph S. Camardo Senior Vice President-Global Medical Affairs
Jay T. Backstrom Chief Medical Officer
Rupert J. Vessey President-Research & Early Development
Sector and Competitors
1st jan.Capitalization (M$)
CELGENE CORPORATION50.18%67 959
JOHNSON & JOHNSON7.03%368 416
PFIZER-4.54%233 461
ROCHE HOLDING LTD.9.84%228 186
NOVARTIS13.31%210 460
MERCK AND COMPANY5.98%208 495